SCCR 29 December 11, 2014 Plenary on L&E for Libraries and Archives: a Few General Statements
SCCR29 December 11, 2014 Plenary regarding limitations and exceptions for Libraries and Archives
Search Results for: ustr
SCCR 29 Libraries, Archives and Public Interest NGOs in Q&A with Dr. Crews
While the many publishers representatives took the floor to explain that there are truly no problems with limitations and exceptions for libraries and archives (and anyway according to them if there are problems that can be solved with licenses), libraries & archives as well as public interest groups make their case: the committee must continue its work on limitations and exceptions for libraries and archives and find solutions.. Here are excerpts from some of the interventions:
SCCR 29: Statements by European broadcasters and push back by copyright owners (IFPI & FIAP)
SCCR29 At 3pm, the plenary reconvened and the NGOs made their statements regarding the rights, definitions and concepts of the proposed broadcasting treaty discussed during the informal with the help of charts.
On the public interest side we only had KEI, TACD, EFF and CIS. I will post these statements in another blog. Here are 3 statements that are good examples of what the arguments were for the broadcasters (the European Broadcasting Union) followed by the push back by the IFFPI (representing the music industry) and finally the FIAP (film industry also pushing back).
SCCR 29 Morning Session: Is the Broadcasting Treaty crawling back?
The morning session of SCCR 29 (Dec 8-12, 2014) ended with a coffee break which will be followed by informals (that we are not allowed to report on at this point). After the usual decisions this morning i.e, Adoption of the agenda of the twenty ninth session then Accreditation of new non governmental organizations (and yes, the Program on Information Justice and Intellectual Property (PIJIP) is in!) we had the Adoption of the Report of the Twenty-Eighth Session of the Standing Committee on Copyright and Related Rights. Continue Reading
KEI comment on the new Tufts Study on Drug Development Costs
The Tuft Center for Study of Drug Development (CSDD) has just concluded a press conference, and issued a press release about their new study of drug development costs. The key number is $2.558 billion.
KEI Research Note: Size of Clinical Trials, data from the FDA 2010 NME and BLA approvals, preliminary results
A copy of the research note is also available here as a pdf file: /wp-content/uploads/kei-rn-2014-3.pdf
KEI Research Note 2014:3
Size of Clinical Trials, data from the FDA 2010 NME and BLA approvals, preliminary results
Elizabeth Rajasingh
November 17, 2014
Introduction
Former WTO Director-General, Pascal Lamy, mooted to chair Global Fund’s Equitable Access Initiative
On 14 March 2014, KEI published “Resurrecting the Ghost of Høsbjør Past: Global Fund seeks to establish global framework on tiered pricing enforced by WTO rules” in which we provided an analysis of the Global Fund’s plans to create a global framework for tiered pricing enforced by the rules of the World Trade Organization (WTO). Continue Reading
WIPO patent committee (SCP21) to discuss International Nonproprietary Names and Exceptions and Limitations to Patent Rights
In the words of the International Bureau of the World Intellectual Property Organization (WIPO), the WIPO Standing Committee on the Law of Patents (SCP) was created,
created in 1998 to serve as a forum to discuss issues, facilitate coordination and provide guidance concerning the progressive international development of patent law.
WTO TRIPS Council (October 2014): Statement of India on the Review of the Paragraph 6 system (compulsory licensing for export)
On 28 October 2014, India delivered the following intervention at the WTO TRIPS Council’s annual review of the Paragraph 6 system (designed to facilitate compulsory licensing for export of pharmaceuticals).
In particular, India noted that
Some news stories on cancer prices.
U.S.
October 27, 2014. Bill Saporito, “Hospitals Furious at Cancer-Drug Price Hikes,” Time Magazine.
October 26, 2014. John Fauber, “FDA approves cancer drugs without proof they’re extending lives,” Journal Sentinel.